University of Sydney, Sydney, New South Wales, Australia.
Department of Gynaecological Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Aust N Z J Obstet Gynaecol. 2021 Feb;61(1):11-15. doi: 10.1111/ajo.13297. Epub 2021 Jan 5.
Clinical trials of heated intraperitoneal chemotherapy (HIPEC ) for the treatment of advanced ovarian cancer are showing promising survival outcomes. HIPEC has the potential to eliminate ovarian cancer cells from peritoneal surfaces more effectively than systemic chemotherapy through enhanced pharmacokinetic and hyperthermia effects. However, many questions remain to be answered, particularly regarding the true place of HIPEC in the current era of new and effective targeted treatments. Concerns around the potential for increased morbidity, adverse effects on quality of life, and increased resource use following HIPEC use, can only be properly evaluated with ongoing high-quality clinical trials.
针对晚期卵巢癌的腹腔内热化疗(HIPEC)临床试验显示出有希望的生存结果。与全身化疗相比,HIPEC 通过增强药代动力学和热疗作用,有潜力更有效地消除腹膜表面的卵巢癌细胞。然而,仍有许多问题有待解答,特别是 HIPEC 在当前新型有效靶向治疗时代的真正地位。对于 HIPEC 应用后发病率增加、对生活质量的不良影响以及资源使用增加的潜在风险,只有通过正在进行的高质量临床试验才能进行适当评估。